Get notified regarding key financial metrics and revenue changes at ArsanisLearn more
Banner background

Summary - Funding Rounds

Founding Date

2010

Total Funding

$100.2 m

Investors

In total, Arsanis had raised $100.2 m. Arsanis is a subsidiary of X4 Pharmaceuticals

Arsanis Income Statement

Annual

USDFY, 2015FY, 2016FY, 2017

R&D expense

12.7m17.8m28.1m

General and administrative expense

2.1m6.5m8.0m

Operating expense total

14.8m24.3m36.1m

EBIT

(14.8m)(24.3m)(36.1m)

Interest expense

472.0k2.5m2.1m

Interest income

214.0k

Net Income

(13.2m)(23.0m)(33.9m)

Arsanis Balance Sheet

Annual

USDFY, 2015FY, 2016FY, 2017

Cash

6.8m3.0m76.8m

Prepaid Expenses

87.0k1.3m1.1m

Current Assets

8.4m5.7m79.5m

PP&E

760.0k519.0k421.0k

Total Assets

9.5m7.6m81.3m

Accounts Payable

423.0k1.6m1.9m

Current Liabilities

6.7m12.1m10.7m

Non-Current Liabilities

7.2m12.3m11.9m

Total Liabilities

13.9m24.3m22.5m

Common Stock

1.0k1.0k15.0k

Additional Paid-in Capital

372.0k991.0k150.8m

Retained Earnings

(35.4m)(58.4m)(92.3m)

Total Equity

(34.3m)(56.6m)58.7m

Financial Leverage

-0.3 x-0.1 x1.4 x

Arsanis Cash Flow

Annual

USDFY, 2015FY, 2016FY, 2017

Net Income

(13.2m)(23.0m)(33.9m)

Depreciation and Amortization

389.0k285.0k195.0k

Accounts Payable

77.0k1.3m182.0k

Cash From Operating Activities

(10.8m)(21.6m)(27.9m)

Purchases of PP&E

(170.0k)(73.0k)(42.0k)

Cash From Investing Activities

(247.0k)(138.0k)34.0k

Long-term Borrowings

(1.0m)(250.0k)(2.3m)

Cash From Financing Activities

11.5m18.1m101.3m

Net Change in Cash

320.0k(3.7m)73.8m

Interest Paid

81.0k291.0k309.0k

Income Taxes Paid

29.0k4.0k

Arsanis Ratios

USDFY, 2015

Financial Leverage

-0.3 x